|
Match
|
Document |
Document Title |
|
|
7615547 |
Granulates containing liposoluble substances and a process for the preparation thereof
A process is described for the preparation of granulates that contain liposoluble and hydrophobic substances, preferably steroidal substances, and that exhibit rapid and excellent...
|
|
|
7605151 |
Nitrate esters of corticoid compounds and pharmaceutical applications thereof
Compounds of the formula
and use of the compounds as medicaments.
|
|
|
7595055 |
Pharmaceutical composition comprising an extract or compounds isolated from Elfvingia applanata for the prevention and the treatment of diabetes and diabetic complications
The present invention relates to a non-polar solvent soluble extract, polyphenol fractions therefrom and the compounds isolated from Elfvingia applanata , which shows a therapeutic activity for...
|
|
|
7582622 |
Steroids having a mixed androgenic and progestagenic profile
The invention provides 19-nor-D-homosteroids, having a mixed androgenic/progestagenic profile, which are orally active, prevent trabecular bone mineral density (BMD) loss, and which lack liver...
|
|
|
7572780 |
Method and kit for reducing the symptoms of peripheral vascular disease
A method for reducing the symptoms of peripheral vascular disease wherein a chemical agent that reduces peripheral vascular hyperreactivity in response to a stimulus for contraction of peripheral...
|
|
|
7572779 |
Oral pharmaceutical products containing 17β-estradiol-3-lower alkanoate, method of administering the same and process of preparation
A pharmaceutical dosage unit for oral administration to a human female comprising a therapeutically effective amount of 17β-estradiol-3-lower alkanoate, most preferably 17β-estradiol-3-acetate,...
|
|
|
7534779 |
Quinol compound and pharmaceutical composition
The subject invention provides a mechanism by which steroidal quinol compounds confer beneficial ophthalmic effects. The subject compounds possess a lipophilic-hydrophilic balance for transcorneal...
|
|
|
7528123 |
Estrogenic estra-1,3,5(10)-trienes with differential effects on the alpha and beta estrogen receptors, having a linear hydrocarbon chain of from 5-9 carbon atoms in position 11
Disclosed is a novel class of steroid compounds based on estradiol, and carrying an 11β-substitution. Said substitution is a hydrocarbon group which may be linear or branched, provided that it...
|
|
|
7521438 |
Combination of loteprednol and β2-adrenoceptor agonists
The invention relates to a novel combination of a soft steroid, in particular loteprednol, and at least one β 2 adrenoceptor agonist for the simultaneous, sequential or separate treatment of...
|
|
|
7482334 |
Therapeutic treatment methods
The invention relates to the use of compounds to ameliorate or treat a condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include...
|
|
|
7459445 |
Estrogenic compounds and topical pharmaceutical formulations of the same
Novel estrogenic compounds of Formula I are provided.
wherein the bond represented by the wavy line may be a single or double bond such that when the wavy line is a single bond, R 1 is...
|
|
|
7456161 |
Use of DHEA and DHEA-sulfate for the treatment of chronic obstructive pulmonary disease
A method for treating or preventing chronic obstructive pulmonary disease (COPD) by using as active agent a non-glucorticoid steroid, analogue thereof, such as dehydroepiandrosterone (DHEA) and...
|
|
|
7456160 |
Formulation
The invention relates to a novel sustained release pharmaceutical formulation adapted for administration by injection containing the compound...
|
|
|
7435757 |
2-substituted D-homo-estra-1,3,5(10)-trienes as inhibitors of 17β-hydroxy steroid dehydrogenase type 1
The invention relates to new 2-substituted D-homo-estra-1,3,5(10)-trienes of general formula I
in which
R 2 means a C 1 -C 8 -alkyl group, a C 1 -C 8 -alkyloxy group or a halogen atom,...
|
|
|
7419972 |
2-substituted estra-1,3,5(10)-trien-17-ones as inhibitors of 17β-hydroxy steroid dehydrogenase type 1
The invention relates to new 2-substituted estra-1,3,5(10)-trien-17-ones of formula I
as well as their pharmaceutically acceptable salts, their methods of manufacture and use as medicaments for...
|
|
|
7402578 |
Methods for inhibiting cognitive deterioration in adults with down's syndrome
This invention generally pertains to the field of psychiatry. In particular, this invention pertains to the discovery that agents capable of inhibiting the binding of cortisol to its receptors can...
|
|
|
7388003 |
Δ15-D-Homosteroids with androgenic action
The invention relates to Δ 15 -D-homosteroids of general formula (I)
process for their production and pharmaceutical compositions that contain these compounds.
The compounds of general...
|
|
|
7371741 |
Estradiol derivatives and pharmaceutical compositions using same
Compositions and methods for treating mammalian disease characterized by undesirable angiogenesis by administering compounds of the general formula:
wherein the variables are defined in the...
|
|
|
7364754 |
Ceramic based nanoparticles for entrapping therapeutic agents for photodynamic therapy and method of using same
The present invention provides methods and compositions for photodynamic therapy. The composition comprises ceramic nanoparticles in which a photosensitive drug/dye is entrapped. The ceramic...
|
|
|
7361646 |
Methods for treating gastroesophageal reflux disease
This invention relates to the discovery that agents capable of inhibiting the biological action of the glucocorticoid receptor can be used in methods for treating gastroesophageal reflux disease in...
|
|
|
7361645 |
Androgenic 7-substituted 11-halogen steroids
The invention relates to 11β-halogen steroids with general formula (I), whereby R 11 is halogen, X—Y-Z represents a group with one of the two structures CH═C—C or CH 2 —C═C and the...
|
|
|
7342004 |
Thioether sulphamate steroids as steroid inhibitors and anti-cancer compounds
There is provided use of a compound of Formula XI:
wherein R 3 is a sulphamate group and at least of R 1 or R 2 is a thioether group as disclosed by the present specification, capable of...
|
|
|
7326697 |
Methods for increasing the therapeutic response to electroconvulsive therapy
This invention generally pertains to the field of psychiatry. In particular, this invention pertains to the discovery that agents which inhibit the binding of cortisol to the glucocorticoid...
|
|
|
7300926 |
Steroidal quinols and their use for estrogen replacement therapy
The present invention relates to novel estrogen-related steroidal quinols and their use as drugs for estrogen replacement therapy. The quinols of the present invention provide improved...
|
|
|
RE39862 |
Unsaturated 14, 15-cyclopropanoandrostanes, a method for their production and pharmaceutical compositions containing these compounds
The invention relates to new unsaturated 14,15-cyclopropano-androstanes of the general formula (I)
to their synthesis and to pharmaceutical compositions, containing these compounds.
The...
|
|
|
RE39861 |
Methods of extended use oral contraception
A method of female contraception involves administering a combination of estrogen and progestin for 60-110 consecutive days in which the daily amounts of estrogen and progestin are equivalent to...
|
|
|
7214672 |
Preventives/remedies for inflammatory airway diseases
A preventive and/or therapeutic agent for inflammatory respiratory tract diseases containing, as an active ingredient, a steroid derivative represented by the following formula (1):
(wherein R...
|
|
|
RE39592 |
Extended release growth promoting two component composition
An extended release composition comprising a first composition comprising growth promoters and a second composition comprising growth promoters and a biodegradable polymer is described. A method of...
|
|
|
7199116 |
Method of modulating the basal metabolic rate of a dieting mammal by administration of a metabolic modulating agent to the dieting mammal
Modulating the metabolism of a dieting mammal by administering to the dieting mammal the metabolic modulating agent 7-oxo DHEA or a pro-drug thereof incapable of in vivo conversion to testosterone.
|
|
|
7196074 |
Methods of making, using and pharmaceutical formulations comprising 7α, 11β-dimethyl-17β-hydroxyestra-4, 14-dien-3-one and 17 esters thereof
Methods of using 7α,11β-dimethyl-17β-hydroxyestra-4,14-dien-3-one (III)
and 17 esters thereof for various hormonal therapies, oral and parenteral dosage forms comprising these actives, and...
|
|
|
7186707 |
Prodrugs for use as ophthalmic agents
The subject invention provides a mechanism by which steroidal quinol compounds confer beneficial ophthalmic effects. The subject compounds possess a lipophilic-hydrophilic balance for transcorneal...
|
|
|
7182960 |
Pharmaceutical compositions for nasal delivery of oestradiol and norethisterone
The present invention relates to a pharmaceutical composition for administration by the nasal route of 17-β-oestradiol and norethisterone.
|
|
|
7179799 |
(3) and (6) substituted estrogenic compounds
Novel estrogenic compounds of Formula I are provided.
wherein the bond represented by the wavy line may be a single or double bond such that when the wavy line is a single bond, R 1 is...
|
|
|
7169769 |
17α-hydroxy-14β-steroids with hormonal effect
This invention relates to steroidal compounds having the formula I
wherein: R 1 is O, (H,H), (H,OH), NOH, whereby OH is optionally etherified or esterified; R 2 and R 3 are independently...
|
|
|
7169768 |
Method of decreasing atherosclerosis and its complications
A method of decreasing atherosclerosis and its complications including but not limited to myocardial infarction, stroke and peripheral vascular disease wherein the method involves administering to...
|
|
|
7157450 |
Nitrate esters of corticoid compounds and pharmaceutical applications thereof
Compounds of the formula
and use of the compounds as medicaments.
|
|
|
7119081 |
Oestrogen-17-sulphamates as inhibitors of steroid sulphatase
There is provided a compound of Formula I
wherein X is a ring system; R 1 is any one of a sulphamate group, a phosphonate group, a thiophosphonate group, a sulphonate group or a sulphonamide...
|
|
|
7098199 |
Steroid sulphatase inhibitors
A method of inhibiting steroid sulphatase activity in a subject in need of same is described. The method comprises administering to said subject a steroid sulphatase inhibiting amount of a ring...
|
|
|
7078395 |
Methods for treating or preventing cancer by preventing, inhibiting or arresting cell cycling
There is provided use of a cyclic compound or a pharmaceutically active salt thereof in the manufacture of a medicament to prevent and/or inhibit and/or arrest cell cycling, wherein the cyclic...
|
|
|
7078057 |
Process for producing nanometer particles by fluid bed spray-drying
Nanometer particles of poorly water-soluble or substantially water-insoluble compound are produced by finely-spraying a non-aqueous solution of said compound into a heated and fluidized bed of...
|
|
|
7053077 |
Use of biogenic estrogen sulfamates for hormone replacement therapy
The invention relates to the use of biogenic estrogen sulfamates for the oral discontinuous application for hormone replacement therapy (HRT). The discontinuous administration takes place in...
|
|
|
7045513 |
DHEA composition and method
Disclosed are improved pharmaceutical formulations comprising dehydroepiandrosterone (DHEA), enriched in selected polymorphic forms, for therapeutic applications. In one embodiment, the formulation...
|
|
|
7045315 |
Methods for modulating expression of exogenous genes in mammalian systems
In accordance with the present invention, there are provided various methods for modulating the expression of an exogenous gene in an isolated cell and in a mammalian subject employing modified...
|
|
|
7037907 |
Estradiol conjugates and uses thereof
A conjugated prodrug of an estradiol compound conjugated to a biological activity modifying agent.
|
|
|
7030104 |
Topical oestroprogestational compositions with a systemic effect
The present invention relates to the field of therapeutic chemistry and more especially to the realization of new galenic forms intended to be applied on the skin. More particularly it relates to...
|
|
|
7026306 |
Steroidal quinols and their use for antioxidant therapy
The present invention relates to novel estrogen-related steroidal quinols and their use as prodrugs for phenolic estrogens and estrogen analogs. The quinols of the present invention provide...
|
|
|
7018993 |
Antiandrogenic agent
A compound pf general formula (I):
wherein, for example,
X 1 and X 2 independently represent a hydrogen atom. R a represents a hydrogen atom or a protecting group for a hydroxyl...
|
|
|
7018992 |
Hormone composition
Twice weekly administration of an analog to a Vagifem tablet which only contains 10 μg of active material has a sufficient effect.
|
|
|
6989378 |
Testosterone derivative
The invention is the novel androgen (7α,17β)-7-methyl-17-[(1-oxoundecyl)oxy]estr-4en-3one (MENT undecanoate). This compound distinguishes favourably from other testosterone derivatives in that it...
|
|
|
6969708 |
Process for the preparation of a high purity composition comprising (7α, 17α)- 17-hydroxy- 7-methyl- 19-nor-17-pregn-5(10)-en-20-yn-3-one
The invention pertains to a process for the preparation of a high purity composition of (7α, 17α)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-o
ne. The process provides for a composition...
|